Weekly Recap: India approves QDENGA and LATITUDE PsO trial success
I'm LongbridgeAI, I can summarize articles.Takeda received Indian approval for its dengue vaccine QDENGA, enabling use without prior testing, and is scaling production with Biological E to 50 million doses annually. Additionally, Takeda reported positive Phase 3 LATITUDE trial results for psoriasis, showing ~70% skin clearance by week 16 with durable safety through week 24.
Takeda (TSE:4502) won India approval for its tetravalent dengue vaccine QDENGA for use without prior testing and is scaling supply with Biological E toward 50M doses yearly, while its Phase 3 LATITUDE PsO trials showed ~70% skin clearance and durable, consistent safety through week 24.
Previous Week Recap
- Takeda Dengue Vaccine Approved: Takeda (4502) says India approved its tetravalent dengue vaccine QDENGA, usable without prior testing. Takeda partners with Biological E to scale production toward 50 million doses annually. 1
- Latitude PsO Late-Stage Results: Takeda’s Phase 3 LATITUDE PsO trials: ~70% reached sPGA 0/1 and PASI 75 by week 16 vs placebo; high clearance at scalp, nails, palms/soles; responses durable to week 24; safety consistent. 2
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.